Breast Cancer Coverage from Every Angle

Investigational AKT Inhibitor in Triple-Negative Breast Cancer

By: Susan Reckling
Posted: Thursday, October 12, 2017

When added to paclitaxel in the first-line treatment of metastatic triple-negative breast cancer, the AKT inhibitor ipatasertib improves progression-free survival and warrants further investigation, according to the results of the LOTUS trial. Sung-Bae Kim, MD, of the University of Ulsan College of Medicine, Seoul, South Korea, and colleagues claimed these may be the first results supporting AKT-targeted therapy for this type of breast cancer. They published their multicenter phase II findings with this oral agent in The Lancet Oncology.

A total of 124 patients with unresectable locally advanced or metastatic disease were randomly assigned for treatment with either paclitaxel plus ipatasertib (62) or paclitaxel plus placebo (62). With a median follow-up of just over 10 months in both groups, median progression-free survival was longer with ipatasertib than without it in the intention-to-treat population (6.2 vs. 4.9 months). And the same was true among the 48 patients who had PTEN-low tumors, with progression-free survival of 6.2 months with ipatasertib and 3.7 months without it.

As for toxicity, patients treated with ipatasertib experienced grade ≥ 3 diarrhea, neutropenia, and decreased neutrophil count more often than those who did not (23% vs. 0%; 10% vs. 2%; and 8% vs. 6%, respectively). No patients in the ipatasertib group reported experiencing colitis.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.